Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, double-blind, double-dummy, randomised, parallel group dose finding study to investigate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation and to compare the safety and tolerability with warfarin.

Next Previous
Trial Profile

A phase 2, double-blind, double-dummy, randomised, parallel group dose finding study to investigate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation and to compare the safety and tolerability with warfarin.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darexaban (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions
  • Acronyms OPAL2
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 02 Apr 2012 EudraCT reports actual initiation date as 28 May 2009.
    • 16 Nov 2011 Planned number of patients changed from 1280 to 1320 as reported by European Clinical Trials Database.
    • 28 Jul 2011 Results of an analysis of the effects of treatment on thrombogenesis markers presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top